Company research / NUTX

Nutex Health Inc. (NUTX)

CIK 0001479681 · Nasdaq · Services-Business Services, NEC

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Nutex Health Inc. reported revenue of $875.26M. Revenue grew 82.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $846.72M.

Key ratios (year ended 2025-12-31)

50.8%
Gross margin
31.5%
Operating margin
8.1%
Net margin
16.7%
Return on year-end equity
82.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-18

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$846.72M$875.26M$479.95M$247.65M$219.29M$331.53M$274.03M$1.37M$1.37M$23.2K$0
Cost of Revenuen/an/an/an/an/a$14.65M$909.8K$830.4K$507.6K$30.5K$0
Gross Profit$434.03M$444.28M$196.26M$34.77M$15.42M$179.28M$157.61M$536.0K$859.4K-$7.3K$0
R&D Expensen/an/an/an/an/a$285.9K$557.3K$768.1K$545.2Kn/an/a
Operating Income$364.27M$275.62M$130.70M-$31.77M-$406.60M$170.26M$153.17M-$6.90M-$840.4K-$5.69M-$448.6K
Depreciation & Amortization$21.00M$20.53M$18.97M$17.59M$13.13M$7.66M$5.90Mn/an/an/an/a
EBITDA$385.27M$296.15M$149.67M-$14.18M-$393.47M$177.93M$159.07Mn/an/an/an/a
Net Income$179.92M$70.79M$52.10M-$45.79M-$424.78M$132.59M$105.97M-$7.12M-$950.1K$582.1K-$7.43M
EPS (Diluted)n/a$10.48$9.69-$10.39-$100.36$0.22$0.18n/an/an/an/a
Total Assets$964.63M$918.52M$655.32M$398.25M$431.75M$394.65M$169.9K$6.69M$449.4K$3.33M$510.8K
Total Liabilities$457.32M$495.09M$466.79M$319.14M$311.42M$203.07M$1.30M$4.83M$1.95Mn/a$6.38M
Long-Term Debtn/an/an/an/an/an/a$0$0$300.0Kn/an/a
Shareholders' Equity$507.31M$423.44M$188.53M$79.11M$120.33M$191.58M$147.37Mn/an/an/a-$5.87M
Cash & Equivalents$205.21M$185.57M$40.64M$22.00M$34.26M$36.12M$26.9K$1.07M$119.3K$9.4K$10.5K
Operating Cash Flow$279.62M$248.12M$23.15M$1.26M$50.61M$173.43M$86.67M-$4.04M-$480.0K-$714.6K-$274.2K
Capital Expenditures$5.45M$2.53M$2.30M$9.50M$14.63M$36.93M$61.19M$84.0K$0n/an/a
Free Cash Flow$274.17M$245.60M$20.85M-$8.24M$35.97M$136.51M$25.48M-$4.12M-$480.0Kn/an/a
Share Repurchases$55.69M$5.00M$0$0n/an/an/an/an/an/an/a
Shares Outstanding6.84M7.09M5.51M4.51M4.33M592.79Mn/a4.65M777.1K116.20M39.71M
Weighted Average Diluted Sharesn/a6.76M5.49M4.41M4.23Mn/an/an/an/an/a39.69M
EPS (Basic)n/a$11.13$10.23-$10.39-$100.36$0.22$0.18n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView